ProCE Banner Activity

Phase I/II Study of TAK-788, an Investigational EGFR/HER2 TKI, in Previously Treated Advanced NSCLC With EGFR Exon 20 Insertions

Slideset Download
Conference Coverage

TAK-788 achieved 43% confirmed ORR in patients with previously treated advanced NSCLC and EGFR exon 20 insertion mutations.

Released: June 11, 2019

Expiration: June 09, 2020

No longer available for credit.

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Astellas Seattle Genetics

Bayer Healthcare Pharma

Blueprint Medicines

Celgene

Novartis Pharmaceuticals Corporation

Puma Biotechnology, Inc.

Taiho Oncology Inc

Tesaro